Neonc Technologies Holdings, Inc. (NTHI) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Calabasas, CA, アメリカ. 現CEOは Amir Farrokh Heshmatpour.
NTHI を有する IPO日 2025-03-26, 8 名の正社員, に上場 NASDAQ Global Select, 時価総額 $103.17M.
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
